AbbVie Inc (ABBV) : Daniel Devine Co scooped up 14,200 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 13, 2016. The investment management firm now holds a total of 46,180 shares of AbbVie Inc which is valued at $2,748,172.AbbVie Inc makes up approximately 1.76% of Daniel Devine Co’s portfolio.
AbbVie Inc opened for trading at $59.5 and hit $60.32 on the upside on Monday, eventually ending the session at $59.88, with a gain of 0.62% or 0.37 points. The heightened volatility saw the trading volume jump to 60,89,417 shares. Company has a market cap of $96,481 M.
Other Hedge Funds, Including , Carnegie Capital Asset Management boosted its stake in ABBV in the latest quarter, The investment management firm added 3,304 additional shares and now holds a total of 126,837 shares of AbbVie Inc which is valued at $7,548,070. AbbVie Inc makes up approx 1.14% of Carnegie Capital Asset Management’s portfolio.Endurance Wealth Management boosted its stake in ABBV in the latest quarter, The investment management firm added 784 additional shares and now holds a total of 113,076 shares of AbbVie Inc which is valued at $6,729,153. AbbVie Inc makes up approx 1.30% of Endurance Wealth Management’s portfolio. Capital Asset Advisory Services added ABBV to its portfolio by purchasing 3,510 company shares during the most recent quarter which is valued at $208,880. AbbVie Inc makes up approx 0.24% of Capital Asset Advisory Services’s portfolio.Trust Co boosted its stake in ABBV in the latest quarter, The investment management firm added 995 additional shares and now holds a total of 3,626 shares of AbbVie Inc which is valued at $212,121. AbbVie Inc makes up approx 0.10% of Trust Co’s portfolio.Proficio Capital Partners boosted its stake in ABBV in the latest quarter, The investment management firm added 2,008 additional shares and now holds a total of 2,300 shares of AbbVie Inc which is valued at $134,550. AbbVie Inc makes up approx 0.11% of Proficio Capital Partners’s portfolio.
On the company’s financial health, AbbVie Inc reported $1.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 29, 2016. Analyst had a consensus of $1.12. The company had revenue of $6400.00 million for the quarter, compared to analysts expectations of $6382.82 million. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.89 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.